Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KZIA declined for three days, in of 337 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on February 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on KZIA as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for KZIA moved below the 200-day moving average on January 22, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for KZIA entered a downward trend on February 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for KZIA just turned positive on January 16, 2025. Looking at past instances where KZIA's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where KZIA advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
KZIA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.474) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). KZIA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (1.586) is also within normal values, averaging (251.221).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KZIA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KZIA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a company, which engages in the business of pharmaceutical research and development
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MSAQX | 22.10 | 0.04 | +0.18% |
Morgan Stanley Inst Asia Opp I | |||
EEMFX | 8.25 | N/A | N/A |
MFS Emerging Markets Equity Research R3 | |||
EKWAX | 66.85 | -1.83 | -2.66% |
Allspring Precious Metals A | |||
VSMSX | 418.31 | -11.58 | -2.69% |
Vanguard S&P Small-Cap 600 Index I | |||
VRTGX | 393.80 | -14.64 | -3.58% |
Vanguard Russell 2000 Growth Index I |
A.I.dvisor indicates that over the last year, KZIA has been loosely correlated with HOOK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if KZIA jumps, then HOOK could also see price increases.
Ticker / NAME | Correlation To KZIA | 1D Price Change % | ||
---|---|---|---|---|
KZIA | 100% | +0.11% | ||
HOOK - KZIA | 66% Loosely correlated | -1.66% | ||
CLNN - KZIA | 33% Poorly correlated | -1.77% | ||
RVMD - KZIA | 29% Poorly correlated | -2.18% | ||
PRTC - KZIA | 28% Poorly correlated | +0.65% | ||
AVCTF - KZIA | 26% Poorly correlated | N/A | ||
More |